<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005060</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 43/99</org_study_id>
    <secondary_id>SWS-SAKK-43/99</secondary_id>
    <secondary_id>EU-99042</secondary_id>
    <nct_id>NCT00005060</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer</brief_title>
  <official_title>A Phase III Trial of Preoperative vs. Postoperative Chemotherapy With Taxotere-Cisplatin-5FU (TCF) in Patients With Locally Advanced Operable Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one chemotherapy drug with surgery may kill&#xD;
      more tumor cells. It is not yet known if chemotherapy followed by surgery is more effective&#xD;
      than surgery followed by chemotherapy for stomach cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying surgery followed by combination&#xD;
      chemotherapy to see how well it works compared to combination chemotherapy followed by&#xD;
      surgery in treating patients with locally advanced stomach cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare, by intention to treat analysis, feasibility and efficacy of 4 courses of&#xD;
           docetaxel, cisplatin, and fluorouracil as preoperative or postoperative chemotherapy in&#xD;
           patients with locally advanced operable gastric carcinoma.&#xD;
&#xD;
        -  Evaluate the predictive values of some biological and molecular tumor parameters on&#xD;
           response to chemotherapy, metastasis and survival in this patient population.&#xD;
&#xD;
      OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified&#xD;
      according to study center, tumor site (affecting the Z-line (cardia carcinoma Siewart II and&#xD;
      III) vs rest of the stomach), and nodal status (positive vs negative). Patients are&#xD;
      randomized to either preoperative chemotherapy followed by surgery (arm I) or surgery&#xD;
      followed by postoperative chemotherapy (arm II).&#xD;
&#xD;
        -  Arm I: Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 4 hours&#xD;
           on day 1, and fluorouracil IV continuously on days 1-14 every 3 weeks. Patients are&#xD;
           evaluated after 2 courses and patients with progressive disease proceed to immediate&#xD;
           surgery. Otherwise, treatment continues for a total of 4 courses in the absence of&#xD;
           unacceptable toxicity or disease progression. Between 3-5 weeks following day 1 of the&#xD;
           last course of chemotherapy, patients undergo gastric resection.&#xD;
&#xD;
        -  Arm II: Patients undergo immediate gastric resection. Beginning 3-6 weeks after surgery,&#xD;
           patients receive 4 courses of docetaxel, cisplatin, and fluorouracil as in arm I.&#xD;
&#xD;
      Quality of life is assessed before the first and third courses of chemotherapy, before and&#xD;
      after surgery, and then at 1, 3, and 6 months.&#xD;
&#xD;
      Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 240 patients (120 per arm) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure measured after completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity measured after completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete resection (RO) and postoperative mortality as measured after surgery</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Taxotere-Cisplatin-5FU preoperatively</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TCF preoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate surgery followed by TCF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery followed by Taxotere-Cisplatin-5FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere-Cisplatin-5FU</intervention_name>
    <description>Preoperatively</description>
    <arm_group_label>Taxotere-Cisplatin-5FU preoperatively</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate surgery</intervention_name>
    <description>Immediate surgery followed by Taxotere-Cisplatin-5FU</description>
    <arm_group_label>Immediate surgery followed by TCF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed locally advanced gastric carcinoma that is considered&#xD;
             operable&#xD;
&#xD;
               -  T3-4, Nx, M0 OR&#xD;
&#xD;
               -  Tx, N+, M0&#xD;
&#xD;
          -  Lymph nodes considered positive by sonography should be at least 2 of the following:&#xD;
&#xD;
               -  Round&#xD;
&#xD;
               -  Echopoor&#xD;
&#xD;
               -  Sharp borders&#xD;
&#xD;
               -  At least 0.5 cm&#xD;
&#xD;
          -  No distant metastases, including peritoneal carcinomatosis&#xD;
&#xD;
               -  CT scan and peritoneal lavage mandatory&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST or ALT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Adequate renal function within limits to allow for treatment with cisplatin&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable cardiac disease requiring treatment&#xD;
&#xD;
          -  No congestive heart failure or angina pectoris even if medically controlled&#xD;
&#xD;
          -  No significant arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within past 6 months&#xD;
&#xD;
          -  Ejection fraction greater than 50% on cardiac sonography or MUGA scan&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy except basal cell carcinoma of the skin or adequately&#xD;
             treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy of any origin (e.g., alcohol, diabetic)&#xD;
&#xD;
          -  No history of anaphylaxis&#xD;
&#xD;
          -  No other serious concurrent illness or medical condition that would preclude study&#xD;
             therapy&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorders (e.g., psychotic&#xD;
             disorders, dementia, or seizures)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent biologic therapy for gastric carcinoma&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No other concurrent chemotherapy for gastric carcinoma&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent endocrine therapy for gastric carcinoma&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy for gastric carcinoma&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior treatment in a clinical trial&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf Morant, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tumor Zentrum ZeTup St. Gallen und Chur</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fuer Tumordiagnostikund Praevention</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

